Drugs / LstCAR019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05571540 | Oct 2022 → Jan 2024 | B-cell acute lymphoblastic leukemia | Kunming Hope of Health Hospital | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LstCAR019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05571540 ↗ |
| Modality | Cell therapy | “universal CAR-T cells(LstCAR019)” NCT05571540 ↗ |
| Route | Intravenous | “LstCAR019 will be administered by vein.” NCT05571540 ↗ |
| Target | CD19 | “targeting CD19” NCT05571540 ↗ |